

## TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING **REJECTION OVER A PRIOR PATENT**

Docket Number (Optional) 015280-169300

In re Application of: Louis E. Henderson et al.

Application No. 09/431,607

Filed: November 1, 1999

For: METHOD FOR IDENTIFYING AND USING COMPOUNDS THAT INACTIVATE HIV-1 AND OTHER RETROVIRUSES BY ATTACKING HIGHLY CONSERVED ZINC FINGERS IN THE VIRAL NUCLEOCAPSID **PROTEIN** 

The owner\* The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services, of 100 percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 154 and 173, as presently shortened by any terminal disclaimer, of prior Patent No. 6,001,555. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the prior patent are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 and 173 of the prior patent, as presently shortened by any terminal disclaimer, in the event that it later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.

Check either box 1 or 2 below, if appropriate.

1. 🛛 For submissions on behalf of an organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the organization.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

2. The undersigned is an attorney of record.

National Institutes of Health Office of Technology Transfer 6011 Executive and Suite 325 Rockville, MD 2552

Terminal disclaimer fee under 37 CFR 1.20(d) is included.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

\*Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner). Form PTO/SB/96 may be used for making this certification. See MPEP § 324.

60163276 v1

08/19/2005 MAHMED1 00000010 201430

09431607

01 FC:2814

65.00 DA

AUG 1 8 2005

Effective on 12/08/2004.		Complete if Known		
Feet pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818).		Application Number	09/431,607	
FOR FY 2005		Filing Date	November 1, 1999	
		First Named Inventor	Henderson, Louis E.	
Applicant claims small entity status. See 37 CFR 1.27		Examiner Name	Shanon A. Foley	
		Art Unit	1648	
TOTAL AMOUNT OF PAYMENT	(\$)65	Attorney Docket No.	015280-169300US	
METHOD OF PAYMENT (check all that apply)				
Check Credit Card Money Order Other (please identify):				
Deposit Account Deposit Account Number: 20-1430 Deposit Account Name: Townsend and Townsend and Crew LLP				
For the above-identified deposit account, the Director is hereby authorized to: (check all that apply)				
Charge fee(s) indicated below Charge fee(s) indicated below, except for the filing fee				
Charge any additional fee(s) or underpayments of fee(s) under 37 CFR 1.16 and 1.17  WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038				
FEE CALCULATION				
1. BASIC FILING, SEARCH, AN		ARCH FEES EX	(AMINATION EEES	
	Small Entity	Small Entity	(AMINATION FEES Small Entity	
<del>-</del>				Fees Paid (\$)
Utility 300			200 100 _	<del></del>
Design 200			130 65 _	·
Plant 200			160 80 _	
Reissue 300 Provisional 200			600 300 _ 0 0	
2. EXCESS CLAIM FEES  Fee Description  Each claim over 20 or, for Reiss Each independent claim over 3 of Multiple dependent claims  Total Claims  -20 or HP =  HP = highest number of total claims paid for Independent claims  -3 or HP =  HP = highest number of independent claim  3. APPLICATION SIZE FEE  If the specification and drawing for each additional 50 sheet	or, for Reissues, each indeport of the following states of page and the following states of page an	pendent claim more the Paid (\$) M  Pe Paid (\$) ———————————————————————————————————	ultiple Dependent Claims Fee (\$) Fee Paid (\$	360 180 <b>5)</b>
Total Sheets				
100 = / 50 = (round <b>up</b> to a whole number) x =				
4. OTHER FEE(S)  Fees Paid (\$)				
Non-English Specification, \$130 fee (no small entity discount)				
Other: Terminal Disclaimer Fee 65				
SUBMITTED BY				
Signature	a South Wack	Registration No. 37,3	Telephone	925-472-5000
				st 16, 2005